Compare MS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | MRK |
|---|---|---|
| Founded | 1924 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.1B | 317.8B |
| IPO Year | 2025 | 1997 |
| Metric | MS | MRK |
|---|---|---|
| Price | $189.81 | $147.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 28 |
| Target Price | ★ $211.50 | $161.53 |
| AVG Volume (30 Days) | 4.7M | ★ 7.2M |
| Earning Date | 10-14-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.43% | 2.31% |
| EPS Growth | ★ 28.43 | 8.01 |
| EPS | ★ 9.93 | N/A |
| Revenue | $34,275,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $17.31 | $3.43 |
| Revenue Next Year | $5.06 | $3.30 |
| P/E Ratio | $19.10 | ★ N/A |
| Revenue Growth | ★ 5.73 | 1.31 |
| 52 Week Low | $152.80 | $92.11 |
| 52 Week High | $232.25 | $157.00 |
| Indicator | MS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 52.68 |
| Support Level | $182.03 | $140.78 |
| Resistance Level | $194.95 | $154.15 |
| Average True Range (ATR) | 4.90 | 3.74 |
| MACD | 1.11 | 0.11 |
| Stochastic Oscillator | 59.09 | 60.87 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of 2025. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).